Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroprusside vs Tirofiban for Slow Flow Prevention in STEMI
NCT03406819Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sodium nitroprusside and tirofiban in ST-elevation myocardial infarction (STEMI) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Thrombolysis in Myocardial Infarction flow grade after stent implantation, Thrombolysis in Myocardial Infarction flow grade after balloon dilatation and 5 more. Status: unknown.
02
Drugs
sodium nitroprussidetirofiban
03
Conditions
ST-elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03406819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406819.